Relapse in adult idiopathic inflammatory myopathies: clinical predictors and the potential role of anti-NXP2 in a single-center retrospective cohort study
Clinical Rheumatology · 2026-11 · 45 (11) · 6859-6869
DOI: 10.1007/s10067-026-08374-7 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Rheumatology, online erschienen am 05.09.2026. Verfasst von Mustafa Ekici und 14 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Rheumatology, Hacettepe University, Altındağ, Ankara, Turkey. ekicim@hacettepe.edu.tr. Hauptthemen laut MEDLINE: Myositis, Autoantibodies, DNA-Binding Proteins. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Introduction/Objectives Relapse is a frequent challenge in idiopathic inflammatory myopathies (IIM); however, predictors in adults remain insufficiently defined. This study aimed to determine the relapse frequency and risk factors, with an emphasis on myositis-specific autoantibodies (MSAs), in a Turkish IIM cohort.
Methods
Patients diagnosed with IIM according to established classification criteria between 2017 and 2024 at Hacettepe University Hospital, a referral center were retrospectively analyzed in a single-center cohort. Relapse was defined as a ≥ twofold increase in creatine kinase and/or escalation of immunosuppressive therapy for active muscle or extramuscular disease. Predictors were identified using logistic regression analysis.
Results
A total of 136 patients were included (66.2% female; mean age, 47.6 ± 17.5 years). The mean follow-up period was 5.3 ± 5.9 years. During this period, 46 patients (33.8%) relapsed, with a median time to relapse of 2.86 years (95% CI: 0.73–4.99). In the multivariate analysis, younger age at diagnosis (OR 0.97, 95% CI 0.95–0.99, P = 0.009), anti-NXP2 positivity (OR 5.31, 95% CI 1.24–22.58, P = 0.02), and intravenous immunoglobulin use during induction (OR 2.69, 95% CI 1.16–6.26, P = 0.02) independently predicted relapse. Maintenance immunosuppressive therapy for ≥ 5 years was associated with a significantly delayed relapse (log-rank P = 0.01).
Conclusions
Relapse occurred in one-third of adult patients with IIM. Younger age, anti-NXP2 positivity, and IVIG use independently increased relapse risk, whereas long-term maintenance therapy substantially delayed relapse. These findings highlight the need for long-term immunosuppression and close monitoring of high-risk subgroups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Rheumatology, Hacettepe University, Altındağ, Ankara, Turkey. ekicim@hacettepe.edu.tr.
- Faculty of Medicine, Department of Internal Medicine, Hacettepe University, Altındağ, Ankara, Turkey.
- Faculty of Medicine, Department of Rheumatology, Hacettepe University, Altındağ, Ankara, Turkey.
Zitieren
APA
Ekici, M., İçli, İ. Y., Yardımcı, G. K., Özsoy, Z., Ünaldı, E., Fırlatan, B., Bayram, G. S. K., Bulat, B., Kılıç, L., Kalyoncu, U., Karadağ, Ö., Bilgen, Ş. A., Ertenli, A. İ., Kiraz, S., & Akdoğan, A. (2026). Relapse in adult idiopathic inflammatory myopathies: clinical predictors and the potential role of anti-NXP2 in a single-center retrospective cohort study. Clinical Rheumatology, 45(11), 6859-6869. https://doi.org/10.1007/s10067-026-08374-7
Vancouver
Ekici M, İçli İY, Yardımcı GK, Özsoy Z, Ünaldı E, Fırlatan B, et al. Relapse in adult idiopathic inflammatory myopathies: clinical predictors and the potential role of anti-NXP2 in a single-center retrospective cohort study. Clinical Rheumatology. 2026;45(11):6859-6869. doi:10.1007/s10067-026-08374-7
BibTeX
@article{Ekici2026,
author = {Ekici, Mustafa and İçli, İrem Yıldız and Yardımcı, Gözde Kübra and Özsoy, Zehra and Ünaldı, Erdinç and Fırlatan, Büşra and Bayram, Gözde Sevgi Kart and Bulat, Buğu and Kılıç, Levent and Kalyoncu, Umut and Karadağ, Ömer and Bilgen, Şule Apraş and Ertenli, Ali İhsan and Kiraz, Sedat and Akdoğan, Ali},
title = {Relapse in adult idiopathic inflammatory myopathies: clinical predictors and the potential role of anti-NXP2 in a single-center retrospective cohort study},
journal = {Clinical Rheumatology},
year = {2026},
volume = {45},
number = {11},
pages = {6859--6869},
doi = {10.1007/s10067-026-08374-7}
}
EUVIMED